sr 27897 has been researched along with apomorphine in 3 studies
Studies (sr 27897) | Trials (sr 27897) | Recent Studies (post-2010) (sr 27897) | Studies (apomorphine) | Trials (apomorphine) | Recent Studies (post-2010) (apomorphine) |
---|---|---|---|---|---|
48 | 3 | 16 | 9,205 | 287 | 780 |
Protein | Taxonomy | sr 27897 (IC50) | apomorphine (IC50) |
---|---|---|---|
Tryptophan 5-hydroxylase 1 | Rattus norvegicus (Norway rat) | 0.22 | |
D(2) dopamine receptor | Homo sapiens (human) | 0.0146 | |
Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 7.75 | |
D | Rattus norvegicus (Norway rat) | 0.4744 | |
D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.1432 | |
Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.063 | |
D(2) dopamine receptor | Bos taurus (cattle) | 0.3385 | |
D(1A) dopamine receptor | Homo sapiens (human) | 0.025 | |
D(4) dopamine receptor | Homo sapiens (human) | 0.025 | |
D(1B) dopamine receptor | Homo sapiens (human) | 0.025 | |
Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.063 | |
Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.063 | |
Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 7.75 | |
D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.1432 | |
D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.1432 | |
D(3) dopamine receptor | Homo sapiens (human) | 0.025 | |
Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 7.75 | |
D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0813 | |
E3 ubiquitin-protein ligase Mdm2 | Homo sapiens (human) | 0.205 | |
5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | 1.35 | |
D | Bos taurus (cattle) | 0.3385 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (66.67) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Gueudet, C; Gully, D; Le Fur, G; Santucci, V; Soubrie, P; Thurneyssen, O | 1 |
Arnone, M; Gonalons, N; Gueudet, C; Gully, D; Heaulme, M; Keane, P; Le Fur, G; Poncelet, M; Santucci, V; Thurneyssen, O | 1 |
Felicio, LF; Ferreira, FS; Nasello, AG; Sassatani, AS; Tieppo, CA | 1 |
3 other study(ies) available for sr 27897 and apomorphine
Article | Year |
---|---|
The CCKA receptor antagonist SR 27897 differentially influences the activity of A9 and A10 dopaminergic neurons in the rat.
Topics: Animals; Apomorphine; Benzodiazepinones; Devazepide; Dopamine; Indoleacetic Acids; Male; Mesencephalon; Neurons; Rats; Rats, Sprague-Dawley; Receptors, Cholecystokinin; Sincalide; Thiazoles | 1994 |
Neurobehavioural effects of SR 27897, a selective cholecystokinin type A (CCK-A) receptor antagonist.
Topics: Animals; Apomorphine; Brain; Cyclic GMP; Dose-Response Relationship, Drug; Female; Indoleacetic Acids; Male; Mice; Motor Activity; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Cholecystokinin; Thiazoles | 1993 |
Opposite modulation of apomorphine- or amphetamine-induced stereotypy by antagonists of CCK receptors.
Topics: Amphetamine; Animals; Apomorphine; Benzodiazepinones; Dopamine; Indoleacetic Acids; Male; Phenylurea Compounds; Rats; Rats, Wistar; Receptor, Cholecystokinin A; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Stereotyped Behavior; Thiazoles | 2000 |